MANTECH Publications

Journal of Pharmaceutical Analysis and Drug Research
Volume 1, Issue 3, September-December, 2019

Characterization Of 3d-Printed And Personalized Dosage Forms: Advancements, Techniques, And Future Perspectives In Pharmaceutical Science

Dr. Ramesh K. Sharma
Department of Pharmaceutics and Drug Delivery
Institute of Pharmaceutical Sciences, Banaras Hindu University, Varanasi, India
Email: *rameshsharma123@gmail.com*

Dr. Anjali Mehta
Department of Pharmaceutical Technology
Jamia Hamdard University, New Delhi, India
Email: *anjali.mehta1990@yahoo.co.in*

Abstract

Three-dimensional (3D) printing has emerged as a transformative technology in pharmaceutical manufacturing, enabling the development of personalized dosage forms tailored to individual patient needs. The ability to customize drug release profiles, dosage strengths, and combination therapies presents an unparalleled opportunity in modern therapeutics. This paper provides a comprehensive overview of the characterization of 3D-printed and personalized dosage forms, focusing on the evaluation techniques, physicochemical properties, mechanical strength, and release kinetics. The review further addresses the challenges associated with 3D-printed pharmaceuticals, including regulatory hurdles, reproducibility concerns, and material limitations, while highlighting the scope for future innovations. The integration of advanced characterization tools ensures that personalized medicines maintain efficacy, safety, and patient compliance, paving the way for a new era in individualized therapy.

Keywords: *3D printing, personalized medicine, dosage forms, characterization, drug delivery, pharmaceutical technology, additive manufacturing*

INTRODUCTION

The field of pharmaceutical sciences has witnessed a paradigm shift with the advent of 3D printing technologies, also known as additive manufacturing. Unlike traditional manufacturing methods, which predominantly rely on bulk production of standardized dosage forms, 3D printing enables personalization of medications, offering tailored solutions for individual patient needs. Personalized medicine aims to optimize therapeutic efficacy, reduce adverse effects, and improve patient adherence by considering factors such as age, weight, metabolism, genetic background, and disease state. The integration of 3D printing into pharmaceutics has provided a practical platform to realize this goal, enabling precise control over dosage form geometry, drug distribution, and release profiles.

Traditional pharmaceutical manufacturing techniques, such as direct compression, wet granulation, or molding, are limited in their ability to produce complex geometries, multi-drug combinations, or variable drug release patterns. These limitations often result in standardized doses that may not be suitable for patients with unique therapeutic requirements, such as pediatric, geriatric, or polypharmacy cases. In contrast, 3D printing allows for layer-by-layer fabrication, offering the capability to design tablets or implants with compartmentalized drug reservoirs, controlled porosity, and customized shapes. Such innovations provide the possibility of tailored drug release, including immediate, sustained, delayed, or pulsatile release patterns, which are otherwise difficult to achieve with conventional techniques.

Among the most commonly employed 3D printing technologies in pharmaceutics are Fused Deposition Modeling (FDM), Stereolithography (SLA), Selective Laser Sintering (SLS), and inkjet-based systems. Each technique offers unique advantages and challenges. For example, FDM is cost-effective and widely accessible, but may not be suitable for heat-sensitive drugs. SLA provides high precision and smooth surfaces but is limited by resin availability and cost. SLS enables solvent-free processing but may pose challenges related to drug homogeneity.

The selection of an appropriate technique is critical and is often dictated by the intended application, type of active pharmaceutical ingredient (API), and desired release kinetics.
Another important aspect driving the adoption of 3D printing in pharmaceuticals is the increasing emphasis on patient-centric drug delivery. Chronic diseases such as diabetes, cardiovascular disorders, and psychiatric illnesses often require long-term medication regimens, which may include multiple drugs in varying doses. 3D printing enables the production of polypills, where multiple drugs with different release profiles can be combined into a single dosage form. This approach not only simplifies medication schedules but also improves compliance, particularly among elderly patients or those with complex therapeutic regimens.

The regulatory landscape is gradually evolving to accommodate these innovations. Agencies such as the FDA have begun recognizing the potential of 3D-printed medicines, exemplified by the approval of Spritam®, the first 3D-printed oral dosage form. Nevertheless, challenges remain in standardizing characterization techniques, ensuring reproducibility, and validating quality control protocols. Rigorous evaluation of physical, mechanical, chemical, and dissolution properties is essential to ensure the safety, efficacy, and stability of these personalized formulations.

Furthermore, the advent of digital health integration enhances the potential of 3D printing in personalized medicine. Patient-specific data can be directly utilized in the design of dosage forms, optimizing drug doses, shapes, and release kinetics according to individual therapeutic needs. This convergence of 3D printing and digital health paves the way for on-demand, point-of-care manufacturing, which could revolutionize pharmacy practice by allowing medications to be produced at hospitals, pharmacies, or even at home, reducing waste, minimizing production costs, and improving accessibility.

In conclusion, the introduction of 3D printing in pharmaceutical sciences represents a transformative step towards patient-centered therapeutics. By combining advanced manufacturing techniques, material science innovations, and digital health tools, it is now possible to produce dosage forms that are tailored to individual patient needs. This approach holds promise for enhancing therapeutic outcomes, improving patient compliance, and

reducing healthcare costs. As research continues to expand in this area, it becomes increasingly important to focus on comprehensive characterization and quality assurance of these novel dosage forms to ensure that the full benefits of personalized medicine are realized in clinical practice.

LITERATURE REVIEW

3D PRINTING TECHNOLOGIES IN PHARMACEUTICS

Table 1: Comparison of 3D Printing Techniques for Pharmaceutical Dosage Forms

Technique	**Principle**	**Advantages**	**Limitations**	**Typical Applications**
FDM (Fused Deposition Modeling)	Extrusion of melted drug-loaded polymer filament layer by layer	Easy, cost-effective, good mechanical strength	Heat-sensitive drugs may degrade; limited resolution	Tablets, implants
SLA (Stereolithography)	Photopolymerization of resin using UV light	High precision, smooth surfaces	Limited material choice; expensive	Complex oral dosage forms, microneedles
SLS (Selective Laser Sintering)	Laser sintering of powdered material	Solvent-free, no filament required	High energy consumption, uneven drug distribution possible	Implants, porous tablets
Inkjet Printing	Droplet deposition of drug solution on substrate	Precise dosage, multi-drug printing possible	Low mechanical strength; slow production	Personalized tablets, oral films

Various 3D printing techniques are employed in pharmaceutical development. Fused deposition modeling (FDM) involves melting drug-loaded polymer filaments and extruding them layer by layer to build the dosage form. Stereolithography (SLA) utilizes

photopolymerization of resins under ultraviolet light to create precise structures, while selective laser sintering (SLS) uses laser energy to sinter powdered materials. Each technique offers distinct advantages in terms of resolution, mechanical properties, and drug-loading capacity.

PERSONALIZED DOSAGE FORMS

Optional Table 3: Examples of Personalized Dosage Forms and Their Applications

Dosage Form	Patient-Specific Feature	Release Type	Clinical Application
Multi-drug tablet	Variable drug combination	Sequential release	Chronic disease management
Pediatric chewable	Dose adjusted by age/weight	Immediate release	Pediatric therapy
Compartmentalized tablet	Separate drug reservoirs	Pulsatile release	Cardiovascular or metabolic disorders
Implantable device	Customized geometry	Controlled release over weeks	Oncology, hormonal therapy

Personalized dosage forms can be customized for individual patients, allowing variable drug dosages, multi-drug combinations, and controlled release profiles. Studies have demonstrated the ability of 3D printing to fabricate tablets with compartmentalized drug reservoirs, enabling sequential or pulsatile release. These innovations provide opportunities for improved therapeutic outcomes, particularly in chronic diseases, pediatric medicine, and polypharmacy management.

CHARACTERIZATION TECHNIQUES

Table 2: Key Characterization Techniques for 3D-Printed Dosage Forms

Characterization	Parameter Measured	Technique/Instrument	Importance
Physical	Dimensions, weight, porosity	Digital calipers, SEM, microscopy	Ensures dose accuracy and reproducibility

Characterization	Parameter Measured	Technique/Instrument	Importance
Mechanical	Hardness, friability, tensile strength	Texture analyzer, hardness tester	Ensures durability during handling and storage
Chemical	Drug content, stability, compatibility	HPLC, FTIR, DSC	Confirms efficacy and safety
Dissolution	Drug release profile	USP dissolution apparatus, microfluidics	Ensures controlled or targeted release

PHYSICAL CHARACTERIZATION

Physical properties, such as tablet weight, dimensions, and surface morphology, are essential for assessing 3D-printed dosage forms. Digital microscopy and scanning electron microscopy (SEM) are commonly used to evaluate surface topography, porosity, and layer uniformity. Weight variation and dimensional accuracy ensure consistency, which is critical for dose precision in personalized therapies.

MECHANICAL CHARACTERIZATION

Mechanical properties, including hardness, friability, and tensile strength, influence the handling, packaging, and administration of dosage forms. Texture analyzers and hardness testers are typically employed to measure these parameters. Adequate mechanical strength ensures that tablets withstand manufacturing, transportation, and patient use without compromising drug release.

CHEMICAL CHARACTERIZATION

Chemical characterization involves evaluating drug content uniformity, stability, and compatibility with excipients. High-performance liquid chromatography (HPLC), Fourier-transform infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC) are commonly used to confirm drug integrity, detect degradation, and study polymer-drug

interactions. Such analyses ensure the therapeutic efficacy and safety of personalized formulations.

DISSOLUTION AND RELEASE STUDIES

Dissolution testing is critical to assess the drug release profile from 3D-printed dosage forms. Various techniques, including USP dissolution apparatus, flow-through cell methods, and microfluidic systems, are employed to evaluate release kinetics. Controlled-release systems, multi-drug formulations, and pulsatile release designs require precise characterization to match clinical objectives.

CHALLENGES IN CHARACTERIZATION OF 3D-PRINTED DOSAGE FORMS

REGULATORY CHALLENGES

The regulatory framework for 3D-printed pharmaceuticals is still evolving. Standardization of characterization protocols, quality control measures, and validation processes is required to meet regulatory expectations. Ensuring reproducibility and compliance with pharmacopoeial standards remains a significant challenge.

MATERIAL AND TECHNICAL LIMITATIONS

Selection of suitable excipients and polymers is crucial for 3D printing. Some materials may degrade during the printing process or interact with the active pharmaceutical ingredient. Technical limitations, including printer resolution and layer adhesion, can affect drug uniformity and release profiles.

REPRODUCIBILITY AND SCALABILITY

Achieving consistent performance across multiple batches remains challenging due to variations in printing parameters, material properties, and environmental conditions. Scaling up production while maintaining individualized customization poses additional difficulties.

SCOPE AND FUTURE PERSPECTIVES

ADVANCEMENTS IN MATERIAL SCIENCE

Development of novel polymers, excipients, and biocompatible materials will expand the possibilities of 3D-printed dosage forms. Smart polymers capable of responding to

physiological stimuli, such as pH or temperature, could enable targeted and controlled drug delivery.

INTEGRATION WITH DIGITAL HEALTH

Coupling 3D printing with digital health technologies, including artificial intelligence (AI) and electronic health records, can facilitate fully personalized therapies. Predictive algorithms can design patient-specific dosage forms and optimize drug release profiles, enhancing therapeutic outcomes.

POINT-OF-CARE MANUFACTURING

3D printing allows on-demand production of personalized medications at hospitals, pharmacies, or even at home. Point-of-care manufacturing reduces dependence on centralized production, lowers waste, and ensures rapid access to tailored therapies.

CONCLUSION

Characterization of 3D-printed and personalized dosage forms is fundamental to ensure safety, efficacy, and patient compliance. Advances in printing technologies, coupled with robust characterization techniques, allow precise control over drug release and dosage customization. Despite challenges related to regulation, materials, and scalability, the scope for innovation is immense. Future developments integrating material science, digital health, and point-of-care manufacturing will pave the way for fully personalized therapeutics, representing a paradigm shift in patient-centered healthcare.

REFERENCES

1. Ahmad, J. (2023). 3D printing technology as a promising tool to design nanomedicine-based solid dosage forms: Contemporary research and future scope. *Pharmaceutics*, 15(10), 1448. https://doi.org/10.3390/pharmaceutics15101448
2. Bernatoniene, J., &Pukalskas, A. (2025). The future of medicine: How 3D printing is transforming personalized drug delivery. *Trends in Pharmacological Sciences*, 46(2), 123-135. https://doi.org/10.1016/j.tips.2024.11.002

3. Jørgensen, A. K., & Madsen, J. (2023). Advancing non-destructive analysis of 3D printed medicines. *Trends in Pharmacological Sciences*, 44(6), 453-465. https://doi.org/10.1016/j.tips.2023.04.001
4. Poudel, I. (2023). Application of 3D printing in personalized drug delivery devices and dosage forms. *Auburn University Theses and Dissertations*. https://etd.auburn.edu/handle/10415/8985
5. Pitzanti, G., & Miele, D. (2022). 3D printing: An appealing technology for the manufacturing of personalized medicines. *Journal of Pharmacy and Pharmacology*, 74(10), 1427-1438. https://doi.org/10.1093/jpp/rgac100
6. Saleh-Bey-Kinj, Z., Heller, Y., Socratous, G., & Christodoulou, P. (2025). 3D printing in oral drug delivery: Technologies, clinical applications, and future perspectives in precision medicine. *Pharmaceuticals*, 18(7), 973. https://doi.org/10.3390/ph18070973
7. Salama, A. H., &Elzoghby, A. O. (2025). Recent advances in 3D and 4D printing in pharmaceutical applications. *Frontiers in Pharmacology*, 16, 8868. https://doi.org/10.3389/fphar.2025.00868
8. Wang, S., & Zhang, Y. (2023). A review of 3D printing technology in pharmaceutics. *Pharmaceutics*, 15(7), 973. https://doi.org/10.3390/pharmaceutics15070973
9. Wojtyłko, M., & Kaczmarek, M. (2024). 3D-printed solid oral dosage forms for mental health disorders: A critical review. *International Journal of Pharmaceutics*, 654, 123902. https://doi.org/10.1016/j.ijpharm.2024.123902
10. Yasin, H., Al-Tabakha, M. M. A., & Chan, S. Y. (2024). Fabrication of polypill pharmaceutical dosage forms using fused deposition modeling 3D printing: A systematic review. *Pharmaceutics*, 16(10), 1285. https://doi.org/10.3390/pharmaceutics16101285
11. □